002462 Cachet Pharmaceutical
- 13.12
- -0.08-0.61%
Cachet Pharmaceutical News
Cachet Pharmaceutical's (SZSE:002462) Soft Earnings Are Actually Better Than They Appear
The market for Cachet Pharmaceutical Co., Ltd.'s (SZSE:002462) shares didn't move much after it posted weak earnings recently. We think that the softer headline numbers might be getting counterbalanc
Jiashitang (002462.SZ) reported 2023 annual results, net profit of 250 million yuan, a year-on-year decrease of 15.79%
Jiashitang (002462.SZ) released its 2023 annual report. The company achieved 299 operating income during the reporting period...
Jiashitang (002462.SZ): Zhao Baofu no longer holds the position of director
Jiashitang (002462.SZ) announced that the company recently received information from the shareholder China Everbright Group Co., Ltd. about the company...
Benign Growth For Cachet Pharmaceutical Co., Ltd. (SZSE:002462) Underpins Stock's 30% Plummet
Cachet Pharmaceutical Co., Ltd. (SZSE:002462) shareholders that were waiting for something to happen have been dealt a blow with a 30% share price drop in the last month. Instead of being rewarded,
The Returns On Capital At Cachet Pharmaceutical (SZSE:002462) Don't Inspire Confidence
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increa
[Instant Analysis of BT Financial Report] Jiashitang's 2023 Interim Report: Operating income has increased steadily, net cash flow has increased dramatically
The 2023 interim report of Jiashitang (stock code: 002462) has been published. This article will interpret its financial data from the perspective of a financial analyst. First, let's take a look at Jiashitang's revenue. Revenue for the reporting period was 14,877,717,780.55 yuan, an increase of 17.09% compared to 12,706,434,721.05 yuan for the same period last year. This is mainly due to the increase in revenue from the pharmaceutical wholesale business. However, the net profit attributable to shareholders of listed companies during the reporting period was 155,489,204.07 yuan, compared with 169 in the same period last year.
Investors Can Find Comfort In Cachet Pharmaceutical's (SZSE:002462) Earnings Quality
Soft earnings didn't appear to concern Cachet Pharmaceutical Co., Ltd.'s (SZSE:002462) shareholders over the last week. We did some digging, and we believe the earnings are stronger than they seem.
Jiashitang (002462.SZ): Net profit fell 8.26% in the first half of the year to 155 million yuan
Glonghui, August 30, 丨 Jiashitang (002462.SZ) announced its 2023 semi-annual report. Operating revenue for the reporting period was 14.878 billion yuan, up 17.09% year on year; net profit attributable to shareholders of listed companies was 155 million yuan, down 8.26% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 149 million yuan, down 7.87% year on year; basic earnings per share.
Is Cachet Pharmaceutical (SZSE:002462) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Jiashitang (002462.SZ): Currently, all pharmacy chains are directly managed, and no pharmacy franchise matters have been launched
GLONGHUY July 5: Some investors asked Jiashitang (002462.SZ), “Can the company join the pharmacy chain?” In response, Carshitang said that currently all of the company's pharmacy chains are directly managed, and no pharmacy franchise matters have yet been initiated.
Slowing Rates Of Return At Cachet Pharmaceutical (SZSE:002462) Leave Little Room For Excitement
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd like to see a company investing more capital into its business and ideally the
Positive Earnings Growth Hasn't Been Enough to Get Cachet Pharmaceutical (SZSE:002462) Shareholders a Favorable Return Over the Last Five Years
Cachet Pharmaceutical Co., Ltd. (SZSE:002462) shareholders should be happy to see the share price up 11% in the last month. But that doesn't change the fact that the returns over the last five year
Can Mixed Fundamentals Have A Negative Impact on Cachet Pharmaceutical Co., Ltd. (SZSE:002462) Current Share Price Momentum?
Most readers would already be aware that Cachet Pharmaceutical's (SZSE:002462) stock increased significantly by 21% over the past three months. But the company's key financial indicators appear to b
Cachet Pharmaceutical's (SZSE:002462) Returns On Capital Not Reflecting Well On The Business
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongsi
Here's Why Cachet Pharmaceutical (SZSE:002462) Has A Meaningful Debt Burden
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Jiashitang's latest announcement: net profit in the first three quarters increased by 8.43% to 266 million yuan
Jiashitang released its report for the third quarter of 2021 that the company's operating income in the first three quarters was 19.351 billion yuan, an increase of 18.80 percent over the same period last year. The net profit belonging to shareholders of listed companies was 266 million yuan, up 8.43 percent from the same period last year; the net profit belonging to shareholders of listed companies after deducting non-recurring profits and losses was 258 million yuan, up 8.09 percent from the same period last year; and basic earnings per share was 0.91 yuan. According to the 2021 report of Jiashitang, the company's main income was 12.562 billion yuan, up 29.35% from the same period last year; the net profit from its mother was 175 million yuan, up 29.12% from the same period last year; and 170 million was deducted from non-net profit.
Analysis
Price Target
No Data
